论文部分内容阅读
目的:研究观察应用卡培他滨联合长春瑞滨治疗晚期乳腺癌的近期临床疗效及毒副反应。方法:卡培他滨2000mg/m2,2次/d口服,第1~14天;长春瑞滨25mg/m2快速静脉滴注,第1,8天,21天为1周期,所有病例均接受化疗2~4个周期。结果:35例患者中,均可行疗效及毒性评价,其中CR 4例(11.43%),PR 14例(40.00%),SD 12例(34。28%),PD 5例(14.28%)总有效率(CR+PR)为51.42%。结论:卡培他滨联合长春瑞滨治疗晚期乳腺癌取得了较好的疗效,不良反应可以耐受,值得临床进一步研究。
Objective: To study the short-term clinical efficacy and side effects of capecitabine and vinorelbine in the treatment of advanced breast cancer. Methods: Capecitabine 2000mg / m2, 2 times / d orally, the first to 14 days; vinorelbine 25mg / m2 rapid intravenous infusion, the first 1,8 days, 21 days for a cycle, all patients were treated with chemotherapy 2 ~ 4 cycles. Results: The curative effect and toxicity were all evaluated in 35 patients, including 4 cases (11.43%) in CR, 14 cases (40.00%) in PR, 12 cases (34.28%) in SD and 5 cases (14.28% Efficiency (CR + PR) was 51.42%. Conclusion: Capecitabine combined with vinorelbine has a good curative effect in the treatment of advanced breast cancer. Adverse reactions are tolerable and worth further clinical study.